Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Rhea-AI Summary
Cogent Biosciences (Nasdaq: COGT) will present new data at the European Hematology Association (EHA) 2026 Congress in Stockholm, June 11-14, 2026.
Highlights include a pivotal APEX trial oral presentation in Advanced Systemic Mastocytosis, an AdvSM poster, and a preclinical JAK2 V617F poster on CGT1145.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers in Biotechnology showed mixed moves with both gains (e.g., DYN up 5.13%) and declines (e.g., CLDX down 5%), suggesting this EHA presentation news is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 05 | Earnings and update | Positive | +0.7% | Q1 2026 results, NDAs under review, and cash runway into 2028. |
| Apr 21 | Clinical data update | Positive | -0.7% | Positive Phase 3 PEAK GIST data selected for ASCO oral presentation. |
| Apr 17 | Preclinical pipeline data | Positive | +2.9% | AACR preclinical results for CGT1263 and CGT4255 showing strong selectivity and activity. |
| Apr 01 | NDA submission | Positive | -8.4% | NDA submission for bezuclastinib in imatinib‑resistant GIST with favorable Phase 3 outcomes. |
| Mar 16 | Regulatory milestone | Positive | +5.0% | FDA acceptance of bezuclastinib NDA in NonAdvSM with a set PDUFA date. |
Recent news has been largely positive, but price reactions have alternated between gains and pullbacks, showing mixed alignment with upbeat catalysts.
Over recent months, Cogent has consistently reported advancing milestones for bezuclastinib and its broader oncology pipeline. FDA acceptance of the NonAdvSM NDA with a PDUFA date of December 30, 2026, submission of the GIST NDA with strong Phase 3 data, and positive PEAK results have positioned the company for potential launches. Preclinical oncology posters and Q1 2026 results highlighted substantial R&D investment and a large cash balance. Today’s EHA-focused announcement continues this pattern of clinical and scientific visibility rather than introducing new topline efficacy data.
Market Pulse Summary
This announcement highlights expanded scientific visibility for bezuclastinib and the JAK2 V617F program at the EHA 2026 Congress, including a pivotal APEX AdvSM oral presentation and multiple posters. It adds to a recent cadence of clinical and regulatory milestones for systemic mastocytosis and GIST. Investors may watch for detailed efficacy and safety readouts from APEX, as well as further progress of the JAK2 V617F inhibitor program and other pipeline assets in hematologic malignancies.
Key Terms
advanced systemic mastocytosis medical
jak2 v617f medical
myeloproliferative neoplasms medical
mutant-selective inhibitor medical
AI-generated analysis. Not financial advice.
- Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings
- Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation
WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations from the company’s Advanced Systemic Mastocytosis (AdvSM) program, including an oral presentation highlighting the results of the APEX trial, as well as a poster presentation from its emerging JAK2 V617F program at the European Hematology Association (EHA) Congress being held in Stockholm, Sweden, June 11-14, 2026.
Details of the presentations are as follows:
Bezuclastinib
Oral Presentation
Abstract Title: Efficacy and Safety of Bezuclastinib in Patients With Advanced Systemic Mastocytosis: Primary Results From the Apex Study
Presenter: Daniel DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School
Session Date and Time: June 13, 2026 – 17:15 – 18:30 CEST (11:15 AM ET – 12:30 PM ET)
Oral Session: S438 Myeloproliferative Neoplasms – Clinical
Session Room: A2-3 Hall
Poster Presentation
Abstract Title: The Effect of Bezuclastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results from the Pivotal Apex Trial
Poster #: PF885
Presenter: Tracy George, M.D., President and Chief Scientific Officer at ARUP Laboratories, Professor of Pathology at the University of Utah School of Medicine
Session Date and Time: June 12, 2026 – 18:45-19:45 CEST (12:45pm - 1:45pm ET)
JAK2 V617F
Poster Presentation
Abstract Title: Preclinical characterization of CGT1145 a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Poster #: PF853
Presenter: Mark J Chicarelli, Senior Director Medicinal Chemistry, Cogent Biosciences
Session Date and Time: June 12, 2026 – 18:45-19:45 CEST (12:45pm - 1:45pm ET)
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
